We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.76B
AUM Growth
-$304M
Cap. Flow
+$23.1M
Cap. Flow %
0.49%
Top 10 Hldgs %
26.26%
Holding
167
New
11
Increased
69
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$35.6M
2
WRBY icon
Warby Parker
WRBY
+$35M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$30.4M
4
IMRX icon
Immuneering
IMRX
+$29.3M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$26.3M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$68.6M
2
ARDX icon
Ardelyx
ARDX
+$39.8M
3
BIIB icon
Biogen
BIIB
+$39.3M
4
BSX icon
Boston Scientific
BSX
+$34.2M
5
PPD
PPD, Inc. Common Stock
PPD
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.24%
2 Consumer Staples 1.58%
3 Industrials 0.82%
4 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
76
Collegium Pharmaceutical
COLL
$882M
$17.8M 0.37%
900,000
-20,000
-2% -$432K
RIGL icon
77
Rigel Pharmaceuticals
RIGL
$778M
$17.4M 0.37%
479,340
+3,850
+0.8% +$152K
SPRO icon
78
Spero Therapeutics
SPRO
$71.2M
$17.3M 0.36%
941,543
-24,385
-3% -$391K
LEGN icon
79
Legend Biotech
LEGN
$4B
$15.9M 0.34%
315,218
+2,600
+0.8% +$108K
AMYT
80
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$15.6M 0.33%
+1,295,225
New +$14.6M
KURA icon
81
Kura Oncology
KURA
$874M
$15.4M 0.32%
822,500
+5,700
+0.7% +$107K
RLAY icon
82
Relay Therapeutics
RLAY
$4.37B
$14.8M 0.31%
469,560
+19,302
+4% +$650K
ANAB icon
83
AnaptysBio
ANAB
$1.64B
$14.5M 0.31%
535,832
+600
+0.1% +$15.2K
RXDX
84
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$14.5M 0.3%
610,136
+14,040
+2% +$331K
NEUE
85
DELISTED
NeueHealth
NEUE
$14.4M 0.3%
22,063
-7,625
-26% -$6.71M
CYPH
86
Cypherpunk Technologies Inc
CYPH
$72.4M
$14.1M 0.3%
+350,827
New +$6.6M
NKTX icon
87
Nkarta
NKTX
$176M
$14M 0.29%
503,148
+5,200
+1% +$165K
BMEA icon
88
Biomea Fusion
BMEA
$92.1M
$14M 0.29%
1,165,582
– –
AUPH icon
89
Aurinia Pharmaceuticals
AUPH
$2.06B
$13.6M 0.29%
613,269
-172,500
-22% -$2.74M
MGNX icon
90
MacroGenics
MGNX
$259M
$13.4M 0.28%
641,816
+186,000
+41% +$4.48M
VINC
91
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$12.9M 0.27%
+40,015
New +$11.7M
FULC icon
92
Fulcrum Therapeutics
FULC
$286M
$12.8M 0.27%
+455,290
New +$8.63M
WST icon
93
West Pharmaceutical
WST
$24.8B
$12.7M 0.27%
30,000
+1,500
+5% +$632K
AKRO
94
DELISTED
Akero Therapeutics
AKRO
$12.7M 0.27%
568,701
+40,100
+8% +$908K
SYRE icon
95
Spyre Therapeutics
SYRE
$9.29B
$12.5M 0.26%
63,092
– –
OLK
96
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$12.2M 0.26%
505,000
+80,000
+19% +$2.51M
RCKT icon
97
Rocket Pharmaceuticals
RCKT
$397M
$12.1M 0.25%
403,270
– –
MREO
98
Mereo BioPharma
MREO
$43.5M
$11.7M 0.25%
4,832,978
+290,209
+6% +$768K
APLT
99
DELISTED
Applied Therapeutics
APLT
$11.6M 0.24%
701,680
– –
PRLD icon
100
Prelude Therapeutics
PRLD
$385M
$11.3M 0.24%
362,359
-20,000
-5% -$648K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rock Springs Capital Management held 167 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q3 2021 filing shows 11 new, 69 increased, 16 reduced and 14 closed positions. Its largest new stake was Baxter International: 450,000 shares worth $36.2M. The largest sale was BeOne Medicines Ltd, an estimated $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q3 2021 buy was Baxter International: 450,000 shares worth $36.2M.
  • Rock Springs Capital Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $30.4M increase.
  • Rock Springs Capital Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $14.9M.
  • Rock Springs Capital Management fully exited BeOne Medicines Ltd in Q3 2021, selling an estimated $68.6M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $4.76B portfolio in Q3 2021.
  • Rock Springs Capital Management opened 11 new positions and closed 14 in Q3 2021.
  • Rock Springs Capital Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.